SPY415.87+4.42 1.07%
DIA340.44+2.91 0.86%
IXIC14,038.76+180.92 1.31%

IMV: Maveropepimut-S in Combination With Merck's Keytruda and Low Dose Cyclophosphamide Shows Promising Preliminary Results in Two Solid Cancer Indications in the Basket Trial >IMV.T

IMV: Maveropepimut-S in Combination With Merck's Keytruda and Low Dose Cyclophosphamide Shows Promising Preliminary Results in Two Solid Cancer Indications in the Basket Trial >IMV.T

· 03/17/2021 07:06

Please log in to view news